RAPIDLY EMERGING ANTIVIRAL DRUG DEVELOPMENT INITIATIVE- AViDD CENTER (READDI-AC)

数据摘要/摘要 新出现的病毒突然出现，在全世界造成相当大的发病率和死亡率。准备 当前和未来的威胁，需要公私伙伴关系来改变当前的被动反应 一个平台是主动的。针对快速出现的抗病毒药物RFA-AI-21-050 发展倡议AViDD中心（READDI-AC）是一个综合的公私合作伙伴关系， 跨学科的专家研究团队，他们在病毒学中应用最先进的创新技术， 生物化学、结构生物学、药物化学、计算生物学、结构导向药物设计和 基因组学开发口服，有效，广谱的冠状病毒，黄病毒， 甲病毒和丝状病毒。为了实现这些目标，READDI-AC计划包括学术领袖， 基础和应用抗病毒研究和化学以及行业领导者杨森制药 N.V.（JPNV）、Takeda、Chimerix Inc.和Pardes Biosciences。我们的商业合作伙伴提供了一个令人羡慕的轨道 在药物发现和产品开发方面的记录，以及在药物化学，药理学，药物 制剂、毒性研究和药代动力学，对于推动preIND优化电极导线至关重要 使研究走向临床。重要的是，我们的行业合作伙伴还提供实物匹配捐助， 获得高质量的商业化学品库，早期命中，优化的线索，和最先进的高- 吞吐量屏幕。READDI-AC的近期和长期目标是：a）验证药物靶点， 保守的病毒蛋白，B）使用SAR和现有技术水平的生物化学和酶促鉴定命中物和先导物 c）优化/配制化学探针和先导化合物作为广泛作用的口服化合物， 针对每个新出现的病毒家族的多个相关成员的活性; d）提供关键的后期临床前 为两种广泛活性的口服候选药物开发和IND使能体内研究; e）促进开放 科学共享未使用的化学资产、化学探针、方法、试剂和分析， 众包; f）通过耦合建立21世纪世纪病毒药物发现和开发的能力和培训 利用最先进的技术、集成的工作流程， 以及新颖的发现平台，用于引领进展和SAR优化。Readdi-AC有五项研究 项目和四个高度互动的核心，建立一个合作的景观，建立领导力，专业知识， 反应能力和伙伴关系，为21世纪的药物开发注入活力。

PROGRAM SUMMARY/ABSTRACT Emerging viruses arise suddenly and cause considerable morbidity and mortality worldwide. To prepare for current and future threats, public-private partnerships are needed to change the current reactive response platform into one that is proactive. In response to RFA-AI-21-050, the Rapidly Emerging Antiviral Drug Development Initiatives AViDD Center (READDI-AC) is an integrated public-private partnership with a renowned, interdisciplinary research team of experts, who apply cutting edge innovative technologies in virology, biochemistry, structural biology, medicinal chemistry, computational biology, structure-guided drug design and genomics to develop oral, potent, broad-spectrum family-specific antivirals for coronaviruses, flaviviruses, alphaviruses and filoviruses. To achieve these goals, the READDI-AC program includes academic leaders in basic and applied antiviral research and chemistry as well as industry leaders Janssen Pharmaceuticals N.V.(JPNV), Takeda, Chimerix Inc. and Pardes Biosciences. Our commercial partners provide an enviable track records in drug discovery and product development, and leadership in medicinal chemistry, pharmacology, drug formulation, toxicity studies and pharmacokinetics, especially critical for driving optimized leads through preIND enabling studies toward the clinic. Importantly, our industry partners also provide in kind matching contributions, access to high quality commercial chemical libraries, early hits, optimized leads, and state of the art high- throughput screens. The immediate and long-term goals of READDI-AC are to: a) validate druggable targets in conserved viral proteins, b) identify hits and leads using SAR and state of the art biochemical and enzymatic assays, c) optimize/formulate chemical probes and lead compounds as broadly acting oral compounds with activity against multiple relevant members of each emerging virus family; d) provide critical late-stage preclinical development and IND-enabling in vivo studies for two broadly active, oral drug candidates; e) promote open science sharing of unused chemical assets, chemical probes, methods, reagents and assays for innovations by crowdsourcing; f) build capacity and training in 21st century viral drug discovery and development by coupling innovative approaches in target discovery and validation with state of the art techniques, integrated workflows and novel discovery platforms for hit to lead progression and SAR optimization. READDI-AC has five Research Projects and four highly interactive cores that establish a cooperative landscape that builds leadership, expertise, response capacity and partnerships that invigorate 21st century drug development.